Peter Ballard

5.1k citations

45 papers · 1.4k indexed · 1 hit paper · h-index 19

Impact in

Oncology top 5%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment

Papers in ⓘ

Oncology 20
- HER2/EGFR in Cancer Research 13
- Drug Transport and Resistance Mechanisms 4
Pulmonary and Respiratory Medicine 15
- Lung Cancer Treatments and Mutations 13

Co-authors: Mireille Cantarini (4 shared papers)Kathryn Pickup (2 shared papers)Darren A.E. Cross (7 shared papers)James Yates (4 shared papers)James Chih‐Hsin Yang (2 shared papers)Pasi A. Jänne (3 shared papers)Jonas Malmquist (1 shared paper)Kenneth S. Thress (1 shared paper)
Journals: Bioorganic & Medicinal Chemistry Letters (10 papers)Journal of Pharmaceutical and Biomedical Analysis (5 papers)Molecular Cancer Therapeutics (3 papers)Pharmaceutical Research (3 papers)Annals of Oncology (2 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Peter Ballard

45 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity 2016 · 523 citations

Peers

Countries citing papers authored by Peter Ballard

Since Specialization

Citations

This map shows the geographic impact of Peter Ballard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ballard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ballard more than expected).

Fields of papers citing papers by Peter Ballard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ballard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ballard. The network helps show where Peter Ballard may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Ballard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Ballard Line = papers co-authored together Peter Ballard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity Clinical Cancer Research ·Peter Ballard, James Yates, Zhenfan Yang, Dong‐Wan Kim, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, Mike Hickey, Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne, Darren A.E. Cross Hit paper breakdown →	2016	523
2	Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor Drug Metabolism and Disposition ·Paul A. Dickinson, Mireille Cantarini, J. Collier, Paul Frewer, Scott Martin, Kathryn Pickup, Peter Ballard	2016	105
3	Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Richard Ducray, Peter Ballard, Bernard Barlaam, Mark Hickinson, Jason G. Kettle, Donald Ogilvie, Catherine B. Trigwell	2007	70
4	Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells Atherosclerosis ·Linda K. Buckett, Peter Ballard, Robert G. Davidson, C. R. Dunkley, Lenox D. Martin, John M. Stafford, Fergus McTaggart	2000	53
5	Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label CPT Pharmacometrics & Systems Pharmacology ·Venkatesh Pilla Reddy, Michael L. Walker, Pradeep Sharma, Peter Ballard, Karthick Vishwanathan	2018	53
6	Determination of microsome and hepatocyte scaling factors forin vitro/*in vivoextrapolation in the rat and dog Xenobiotica* ·Roy E. Smith, Rhys D.O. Jones, Peter Ballard, Heledd Jarosz-Griffiths	2008	49
7	The right compound in the right assay at the right time: an integrated discovery DMPK strategy Drug Metabolism Reviews ·Peter Ballard, Patrick Brassil, Khanh Bui, Hugues Dolgos, Carl Petersson, Anders Tunek, Peter J. H. Webborn	2012	37
8	Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer Bioorganic & Medicinal Chemistry Letters ·Robert H. Bradbury, Neil J. Hales, Alfred A. Rabow, Graeme E. Walker, David Acton, David Andrews, Peter Ballard, Nigel Brooks, Nicola Colclough, Alan Girdwood, Urs J. Hancox, Owen D. Jones, David A. Jude, Sarah A. Loddick, Andrew Mortlock	2011	36
9	Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104 Molecular Cancer Therapeutics ·James Yates, Susan Ashton, Darren A.E. Cross, Martine J. Mellor, Steve Powell, Peter Ballard	2016	34
10	5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase Bioorganic & Medicinal Chemistry Letters ·Peter Ballard, Robert H. Bradbury, Laurent Hennequin, D. Mark Hickinson, Paul D. Johnson, Jason G. Kettle, Teresa Klinowska, Rémy Morgentin, Donald Ogilvie, Annie Olivier	2005	31
11	Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors ACS Medicinal Chemistry Letters ·Bernard Barlaam, Judith Anderton, Peter Ballard, Robert H. Bradbury, Laurent Hennequin, D. Mark Hickinson, Jason G. Kettle, George Kirk, Teresa Klinowska, Christine Lambert‐van der Brempt, Cath Trigwell, John P. Vincent, Donald Ogilvie	2013	31
12	Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket Bioorganic & Medicinal Chemistry Letters ·Peter Ballard, Robert H. Bradbury, Craig S. Harris, Laurent Hennequin, Mark Hickinson, Paul D. Johnson, Jason G. Kettle, Teresa Klinowska, Andrew G. Leach, Rémy Morgentin, Martin Pass, Donald Ogilvie, Annie Olivier, Nicolas Warin, Emma Williams	2005	31
13	Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo Bioorganic & Medicinal Chemistry Letters ·Richard Luke, Peter Ballard, David Buttar, Leonie Campbell, Jon Curwen, Steve Emery, Alison M. Griffen, Lorraine Hassall, Barry R. Hayter, Cliff Jones, William McCoull, Martine J. Mellor, Mike L. Swain, Julie A. Tucker	2009	31
14	Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics Bioorganic & Medicinal Chemistry Letters ·Peter Ballard, Robert H. Bradbury, Craig S. Harris, Laurent Hennequin, Mark Hickinson, Jason G. Kettle, Jane Kendrew, Teresa Klinowska, Donald Ogilvie, Stuart E. Pearson, Emma Williams, Ingrid Wilson	2006	29
15	Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors To Explore a MEK Resistance Hypothesis Journal of Medicinal Chemistry ·Jason G. Kettle, Peter Ballard, Catherine Bardelle, Mark Cockerill, Nicola Colclough, Susan E. Critchlow, J.E. Debreczeni, Gary Fairley, Shaun Fillery, M. A. Graham, Louise Goodwin, Sylvie M. Guichard, Kevin Hudson, Richard A. Ward, David Whittaker	2015	28
16	Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase Bioorganic & Medicinal Chemistry Letters ·Peter Ballard, Bernard Barlaam, Robert H. Bradbury, Allan Dishington, Laurent Hennequin, D. Mark Hickinson, Ian Hollingsworth, Jason G. Kettle, Teresa Klinowska, Donald Ogilvie, Stuart E. Pearson, James S. Scott, Abid Suleman, Robin Whittaker, Emma Williams, Robin Wood, Lindsay Wright	2007	23
17	Prediction of in vivo tissue distribution from in vitro data 1. Experiments with markers of aqueous spaces. Pharmaceutical Research ·Peter Ballard, David E. Leahy, Malcolm Rowland	2000	22
18	Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure–activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Laurent Hennequin, Peter Ballard, F. Tom Boyle, Bénédicte Delouvrié, Rebecca Ellston, Chris T. Halsall, Craig S. Harris, Kevin Hudson, Jane Kendrew, J. Elizabeth Pease, Helen S. Ross, Peter D. Smith, Jennifer L. Vincent	2006	22
19	A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Peter Ballard, Robert H. Bradbury, Richard Ducray, Hervé Germain, D. Mark Hickinson, Kevin Hudson, Jason G. Kettle, Teresa Klinowska, Françoise Magnien, Donald Ogilvie, Annie Olivier, Stuart E. Pearson, James S. Scott, Abid Suleman, Cath Trigwell, Michel Vautier, Robin Whittaker, Robin Wood	2007	18
20	Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm) Annals of Oncology ·D. Kim, James Chih‐Hsin Yang, Darren A.E. Cross, Peter Ballard, Pan‐Chyr Yang, James Yates, Liang Xie, Mireille Cantarini, Serban Ghiorghiu, Pasi A. Jänne	2014	18

About Peter Ballard

Peter Ballard is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Organic Chemistry, Molecular Biology and Pharmacology, having authored 45 papers that have together received 1.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (13 papers), Lung Cancer Treatments and Mutations (13 papers), Quinazolinone synthesis and applications (10 papers), Pharmacogenetics and Drug Metabolism (5 papers), Analytical Chemistry and Chromatography (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Drug Transport and Resistance Mechanisms (4 papers) and Estrogen and related hormone effects (3 papers). The work is most often cited by research in Oncology (704 citations), Pulmonary and Respiratory Medicine (670 citations), Pharmacology (112 citations), Organic Chemistry (254 citations) and Genetics (74 citations). Peter Ballard has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Mireille Cantarini, Kathryn Pickup, Darren A.E. Cross, James Yates, James Chih‐Hsin Yang, Pasi A. Jänne, Jonas Malmquist, Kenneth S. Thress, Matthew Grist and Peter Johnström. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Pharmaceutical and Biomedical Analysis, Molecular Cancer Therapeutics, Pharmaceutical Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact